LearnGlossaryMarketStocksSuperinvestorsSign in

RLAY

Relay Therapeutics, Inc.

Healthcare · $3.9B market cap

Verdict

We can't put a fair value on RLAY right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-21.5% a year✗
Sales growth-22.5% a year✗
Free cash flow growth—?
Return on invested capital-47.0%✗

Follow RLAY

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 8, 2026: no open-market purchases and 3 sales worth $1.4M. Why purchases matter

Sales

Patel Sanjiv

President and CEO · 2026-09-08

Sold

$913K

Catinazzo Thomas

Chief Financial Officer · 2026-09-08

Sold

$336K

Bergstrom Donald A

President, R&D · 2026-09-08

Sold

$162K

About Relay Therapeutics, Inc.

Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works